Roth/MKM raises Merlin Labs stock price target on government revenue

Roth/MKM raised Merlin Labs' price target to $25 from $15 while keeping a Buy rating, implying meaningful upside from the current $15.75 share price. The firm said 4Q25 results were largely in line with expectations and left forecasts unchanged, while noting the business remains funded to execute its plan for the next few years. Merlin has posted 514% revenue growth over the last twelve months to $7.55 million, with most sales still coming from U.S. government programs and a ramp expected ahead.

Analysis

The bigger read-through is not the price target hike itself, but that the company is moving from narrative to contract-realization risk. When a software/hardware autonomy story is still concentrated in a few government programs, the stock is effectively trading a long-duration option on procurement cadence; that makes quarterly execution and budget timing far more important than the headline growth rate. In that setup, upgrades can extend multiple expansion, but they also increase the probability of a sharp air pocket if the next ramp is slower than implied.

The near-term catalyst is less about unit economics and more about evidence of repeatability: additional program wins, larger deployment scope, and clearer conversion from pilot activity to billable revenue over the next 2-3 quarters. The key second-order effect is competitive: successful government adoption tends to validate the category and can pull in better-capitalized primes and legacy avionics vendors, which may compress future pricing power even if it expands the market. That means the company’s strongest moat is probably integration velocity and certification progress, not raw AI sophistication.

The main risk is valuation reset if the market starts discounting the gap between market cap and near-term revenue base. With a small revenue denominator, any delay in program ramp can cause multiple compression faster than fundamentals can catch up; conversely, one or two incremental wins can re-rate the name disproportionately. The contrarian view is that the move may be overextended in the short run: the stock has already priced in a meaningful amount of execution, while the actual evidence still looks early-stage and lumpy.

For multi-quarter investors, this is a classic ‘own the catalyst, respect the tape’ setup. The setup is most attractive if management keeps adding credibility through guidance consistency and hiring that supports commercial scaling, but the downside case is that expectations outrun contract velocity. In other words, the stock can work if the next 6-12 months deliver visible backlog conversion; if not, the market will likely de-rate it as a funded story rather than a scaled operating business.

Key Decisions for Investors

• Tactically trim into strength over the next 1-2 weeks if the stock remains extended; use a trailing stop rather than a hard fundamental exit because the name can re-rate violently on new program news.
• For investors wanting exposure, wait for a post-rally consolidation or a 10-15% pullback before initiating a starter long; the risk/reward is better when expectation inflation resets.
• Buy a 3-6 month call spread instead of common equity to express upside to the next catalyst window while capping downside from a valuation unwind.
• If liquid options exist, consider a short-dated put spread as a hedge against a ‘good-but-not-good-enough’ quarter, since small-cap defense/AI names often gap down on any mismatch between story and realized revenue.
• Relative value: long Merlin vs short a legacy avionics/defense tech peer basket if you want to isolate autonomy adoption beta; the pair benefits if procurement continues to favor software-led platforms over hardware incumbents.